Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutch nationwide study of romosozumab use and outcomes
NL-OMON61747Not yet recruiting
- Sponsor
- VieCuri Medisch Centrum
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of romosozumab in osteoporosis, sponsored by VieCuri Medisch Centrum. Primary endpoint: Treatment completion rate with romosozumab. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NL-OMON61747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61747.